Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes
Movement Disorders · 2023
DOI: 10.1002/mds.29555 ↗Kurz gefasst
Kommentar in der Zeitschrift Movement Disorders, 2023. Verfasst von Max Borsche und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neurogenetics, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Parkinsonian Disorders, Parkinson Disease, Multiple System Atrophy. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Parkinson’s disease (PD) is still diagnosed clinically, entailing the consequences that the disease is diagnosed rather late in the neurodegenerative process and that differentiating idiopathic from atypical PD, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), is challenging, particularly in the early stages. Thus, reliable and robust biomarkers are urgently needed in idiopathic and atypical PD. Recently developed α-synuclein seeding assays (SAAs) potentially represent such a biomarker and have become increasingly established in cerebrospinal fluid (CSF) and tissue. However, blood-based assays, investigating a more easily accessible biospecimen, are still very scarce. Moreover, robust tests distinguishing different types of synucleinopathies, such as PD, MSA, and dementia with Lewy bodies (DLB) on an individual level, are not available in clinical practice thus far. Okuzumi et al. present a modified SAA called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC). Different from a recent successful approach addressing neuron-derived exosomes, the newly developed assay targets α-synuclein seeds in serum. The assay accurately distinguishes PD (and DLB) from healthy controls in two internal and one external cohort (area under the curve for PD 0.90). Furthermore, α-synuclein fibrils were also detected in MSA patients, but with lower specificity than in PD, whereas, as expected, patients with the tauopathy PSP showed very low SAA positivity (3%, 1/29). Emphasizing the utility of the new assay, Okuzumi et al. found perfect accordance of the blood-based assay with post-mortem findings in a small subset of PD patients. Regarding prodromal disease phases, they detected α-synuclein seeding in 4/9 individuals with rapid eye movement (REM)-sleep behavior disorder (RBD). However, besides investigating this small sample of RBD patients, analysis and replication in independent cohorts were only performed cross-sectionally in individuals with manifest disease. Thus, conclusions regarding the assay’s capability to identify prodromal disease states are limited. Finally, Okuzumi et al. performed in vivo propagation studies in mice, further supporting the biological underpinnings behind the new method. Of further note, the authors detected different fibril conformations comparing Lewy body disease (LBD, including PD and DLB) and MSA performing electron microscopy (eg, “paired” and “bundled” filaments in LBD and “twisted” and “straight” filaments in MSA). This finding is of relevance, as it demonstrates that differences between these synucleinopathies can be detected in blood, which will be crucial for potential diseasespecific trials. Blood-based SAAs have the potential to profoundly change PD diagnosis, including the differentiation from PD mimics and the separation from other types of synucleinopathies as well as the detection of underlying molecular alterations before motor signs allow a clinical diagnosis. Although the latter aspects require further studies in longitudinal cohorts and replication of these SAAs in larger samples and by independent laboratories, they may pave the way into a new era of diagnosing PD, with profound implications for treatment trials and finally also clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
- Department of Neurology, University Hospital Schleswig-Holstein Campus Lübeck and University of Lübeck, Lübeck, Germany.
- Department of Neurology, University Hospital Schleswig-Holstein Campus Kiel and Kiel University, Kiel, Germany.
ORCID-Profile: Max Borsche
Zitieren
APA
Borsche, M., & Berg, D. (2023). Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes. Movement Disorders. https://doi.org/10.1002/mds.29555
Vancouver
Borsche M, Berg D. Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes. Movement Disorders. 2023. doi:10.1002/mds.29555
BibTeX
@article{Borsche2023,
author = {Borsche, Max and Berg, Daniela},
title = {Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes},
journal = {Movement Disorders},
year = {2023},
doi = {10.1002/mds.29555}
}
EUVIMED